19 October 2009
Prognostic significance of immunohistochemical Rac1 expression in survival in early operable non-small cell lung cancer
Kai YuanABCDEF, Chen QianAEFG, Ruheng ZhengAEGMed Sci Monit 2009; 15(11): BR313-319 :: ID: 878233
Abstract
Background
The small GTPases are involved in the regulation of critical cellular functions, such as transcription control, cell cycle, and organization of actin cytoskeleton. Although a number of investigations have established the significance of Rho-family GTPases in several human tumors, there is still little information available on the clinical significance of Rac1 expression in non-small cell lung cancer (NSCLC). Therefore, immunohistologic expression of Rac1 was studied in a tissue microarray of 111 Stage I-II NSCLCs and correlated with clinicopathologic parameters and clinical outcome.
Material and Method
For this retrospective study 111 tissue samples, obtained from anonymized patients with early operable NSCLC (stage I-II), were used to construct a tissue microarray for immunohistochemical study.
Results
Rac1 showed a cytoplasmic pattern of expression in tumor cells, while normal lung components showed negative or weak cytoplasmic staining. Rac1 expression increased significantly with the advancement of the T stage (P<0.01) and the TNM stage (P<0.05). Analysis of overall survival showed that Rac1 expression was related to poor outcome (P=0.012), even in the group of stage I patients (P=0.023). Multivariate analysis showed that Rac1 overexpression was an independent marker for overall survival after adjusting for other prognostic factors (P=0.023).
Conclusions
We found a positive prognostic value of immunohistologically determined Rac1 protein expression and presents Rac1 as a potential unfavorable prognosis biomarker in patients with early operable NSCLC.
Keywords: Proportional Hazards Models, Lung Neoplasms - surgery, Carcinoma, Non-Small-Cell Lung - surgery, rac1 GTP-Binding Protein - metabolism
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952